Listen on the go
CORRECT!
Next question
touchIMMUNOLOGY touchIMMUNOLOGY

Start Learning

Touch Loading image
JOURNALS
Start Learning
Greatest Hits of 2024
touchIN CONVERSATION
Start Learning
Treating moderate-to-severe atopic dermatitis in children and adolescents: Insights from the experts
CE/CME ACCREDITED
touchMDT
Start Learning
Recognizing and managing HLH in the critical care setting: Best practice for the multidisciplinary team
CE/CME ACCREDITED
endoscopic procedure duodenum
JOURNALS
Start Learning
Novel strategy shows potential to reduce insulin dependence in type 2 diabetes
touchEXPERT OPINIONS
Start Learning
Primary biliary cholangitis: Appraising the changing therapeutic landscape
CE/CME ACCREDITED
RMDs: Experts tell you what to expect in 2025
JOURNALS
Start Learning
RMDs: What to Expect in 2025
touchEXPERT BRIEFING
Start Learning
Advances in the treatment of lupus and Sjögren’s disease
Sponsored content
JOURNALS
Start Learning
Turning your Clinical Expertise into Business Success
www.touchimmunology.com
JOURNALS
Start Learning
New data support the efficacy and safety of cendakimab in eosinophilic oesophagitis
JOURNALS
Start Learning
Bridging Bench and Bedside: Future Leader, Dr Sonali Bracken on Autoimmunity, B Cell Research, and the Future of Rheumatology

to view Favourites, Keep Notes and Track CME Credits

Favourites
Bridging Bench and Bedside: Future Leader, Dr Sonali Bracken on Autoimmunity, B Cell Research, and the Future of Rheumatology
View
Advancing Rheumatology Through Innovation, Education and Patient-Centred Care: An Interview with Future Leader Dr Sham Santhanam
View
Novel anti-CD6 monoclonal antibody, itolizumab, showcases proof of concept in ulcerative colitis
View
Key data on pain and prognosis: Clinical insights and implications
View
Honouring Prof. Marcus Maurer
View
Greatest Hits of 2024
View
RheumaPreg 2025: Dr. Vinod Ravindran’s Perspectives and Highlights
View
New data from IMPACT-PLuS suggests early peanut oral immunotherapy has a lasting immunologic impact in children
View
Epinephrine 1mg Nasal Spray Gains Approval for Type I Allergic Reactions in Children Over 4 Years, who Weigh 15 to <30 kg
View
Optimizing Tumour Necrosis Factor Inhibitor Therapy in Rheumatoid Arthritis: Embracing Personalized Medicine
View
Copied to clipboard!
accredited arrow-down-editablearrow-downarrow_leftarrow-right-bluearrow-right-dark-bluearrow-right-greenarrow-right-greyarrow-right-orangearrow-right-whitearrow-right-bluearrow-up-orangeavatarcalendarchevron-down consultant-pathologist-nurseconsultant-pathologistcrosscrossdownloademailexclaimationfeedbackfiltergraph-arrowinterviewslinkmdt_iconmenumore_dots nurse-consultantpadlock patient-advocate-pathologistpatient-consultantpatientperson pharmacist-nurseplay_buttonplay-colour-tmcplay-colourAsset 1podcastprinter scenerysearch share single-doctor social_facebooksocial_googleplussocial_instagramsocial_linkedin_altsocial_linkedin_altsocial_pinterestlogo-twitter-glyph-32social_youtubeshape-star (1)tick-bluetick-orangetick-red tick-whiteticktimetranscriptup-arrowwebinar Sponsored Department Location NEW TMM Corporate Services Icons-07NEW TMM Corporate Services Icons-08NEW TMM Corporate Services Icons-09NEW TMM Corporate Services Icons-10NEW TMM Corporate Services Icons-11NEW TMM Corporate Services Icons-12Salary £ TMM-Corp-Site-Icons-01TMM-Corp-Site-Icons-02TMM-Corp-Site-Icons-03TMM-Corp-Site-Icons-04TMM-Corp-Site-Icons-05TMM-Corp-Site-Icons-06TMM-Corp-Site-Icons-07TMM-Corp-Site-Icons-08TMM-Corp-Site-Icons-09TMM-Corp-Site-Icons-10TMM-Corp-Site-Icons-11TMM-Corp-Site-Icons-12TMM-Corp-Site-Icons-13TMM-Corp-Site-Icons-14TMM-Corp-Site-Icons-15TMM-Corp-Site-Icons-16TMM-Corp-Site-Icons-17TMM-Corp-Site-Icons-18TMM-Corp-Site-Icons-19TMM-Corp-Site-Icons-20TMM-Corp-Site-Icons-21TMM-Corp-Site-Icons-22TMM-Corp-Site-Icons-23TMM-Corp-Site-Icons-24TMM-Corp-Site-Icons-25TMM-Corp-Site-Icons-26TMM-Corp-Site-Icons-27TMM-Corp-Site-Icons-28TMM-Corp-Site-Icons-29TMM-Corp-Site-Icons-30TMM-Corp-Site-Icons-31TMM-Corp-Site-Icons-32TMM-Corp-Site-Icons-33TMM-Corp-Site-Icons-34TMM-Corp-Site-Icons-35TMM-Corp-Site-Icons-36TMM-Corp-Site-Icons-37TMM-Corp-Site-Icons-38TMM-Corp-Site-Icons-39TMM-Corp-Site-Icons-40TMM-Corp-Site-Icons-41TMM-Corp-Site-Icons-42TMM-Corp-Site-Icons-43TMM-Corp-Site-Icons-44TMM-Corp-Site-Icons-45TMM-Corp-Site-Icons-46TMM-Corp-Site-Icons-47TMM-Corp-Site-Icons-48TMM-Corp-Site-Icons-49TMM-Corp-Site-Icons-50TMM-Corp-Site-Icons-51TMM-Corp-Site-Icons-52TMM-Corp-Site-Icons-53TMM-Corp-Site-Icons-54TMM-Corp-Site-Icons-55TMM-Corp-Site-Icons-56TMM-Corp-Site-Icons-57TMM-Corp-Site-Icons-58TMM-Corp-Site-Icons-59TMM-Corp-Site-Icons-60TMM-Corp-Site-Icons-61TMM-Corp-Site-Icons-62TMM-Corp-Site-Icons-63TMM-Corp-Site-Icons-64TMM-Corp-Site-Icons-65TMM-Corp-Site-Icons-66TMM-Corp-Site-Icons-67TMM-Corp-Site-Icons-68TMM-Corp-Site-Icons-69TMM-Corp-Site-Icons-70TMM-Corp-Site-Icons-71TMM-Corp-Site-Icons-72
Close Popup